Who We Are
EpimAb Biotherapeutics Inc is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Utilizing our broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients.
![](/public/uploads/images/20210415/69c609f32ffdd2d1cd072bedaa4f9f24.jpg)
![](/public/assets/images/about/about2.png)
Promising Pipeline Derived From In-House Research
Preclinical and clinical assets address global unmet medical needs
Sustainable first-/best-in-class pipeline with 4 candidates in the clinic
Novel and Proprietary Bispecific Antibody Technology Platform
World-class innovative BsAb platform with strong IP
Rapid and proven bispecific antibody development process that is comparable to that for typical monoclonal antibodies
Seasoned and Well-rounded Management Team with Global Track Records
Dr. Chengbin Wu is a top expert in the BsAb area with a well-established track record
Team includes other industry veterans with complementary experiences from early discovery, clinical development, CMC, to business development and financing
EpimAb Aims to Redefine Bispecific Antibodies (BsAb)
![WXWorkCapture_16551117301910.png undefined](/public/uploads/images/20220613/b87f834e8a0f1b61046416169e273247.png)
EpimAb Milestone
![](/public/assets/images/about/bg3.png)
Join the dynamic team at EpimAb to maximize your potential
and explore cutting-edge science
and explore cutting-edge science